

## Curriculum Vitae

**Name** **Kyong Hwa Park, MD, PhD**  
**Nationality** Korea, Republic of

### Address:

73 Incheon-ro, SungBuk-Gu, 02841, Seoul, Korea  
Office; +82-2-920-6841  
E-mail: khpark@korea.ac.kr

### Current Position:

2018. 3- PRESENT: Professor, Oncology/Hematology, Department of internal medicine, College of medicine, Korea University

### Experience and Positions Held:

2014. 3- 2015. 2: Visiting scientist, Tumor vaccine group in division of Oncology, department of medicine, University of Washington.  
2013. 3- 2018. 2: Associate professor, Korea University  
2009. 3- 2013. 2: Assistant professor, Korea University  
2007. 9- 2009. 2: Full time lecturer, Oncology/Hematology, Korea University  
2007. 6-2007. 8: Clinical Assistant Professor, Oncology/Hematology, Korea University Anam Hospital  
2005. 6-2007. 6: Postdoctoral fellow, Tumor vaccine group in division of Oncology, department of medicine, University of Washington.  
2004. 3-2005. 5: Clinical fellowship in Division of Oncology/Hematology, Internal Medicine, Korea University Hospital, Seoul, Korea.  
1999. 3-2004. 2: Residency in Internal Medicine, Korea University Hospital, Seoul, Korea.  
1998. 3-1999. 2: Rotating Internship, Korea University Hospital, Seoul, Korea.

### Education:

2002-2005 Ph. D., Graduate School, Korea University, College of Medicine, Seoul, Korea.  
1999-2002: Graduate School of Korea University, Master's Course. Majored in Internal Medicine, Seoul, Korea.  
1998: ECFMG Certificate (No. 0-538-258-5).

1990–1998: MD, College of Medicine, Korea University, Seoul, Korea.

### **Particular interest in Oncology – Clinical and Research:**

- ❖ Clinical interest – Peptide based vaccine as an adjuvant treatment for HER-2 overexpressing or ER-negative breast cancer patient
- ❖ Basic research interest – Translational research for the development of peptide based vaccine and T cell therapy in breast and ovarian cancer

### **Research - Awards**

- ❖ Ji-Seok-Young Medical Award : 1998
- ❖ Young investigator travel award : Korean Cancer Study Group, 2002
- ❖ AACR Scholar in training award : American Association of Cancer Research, 2004
- ❖ Vision 2010 scholarship : Korea University Medical school, 2005

### **Societies Membership**

- ❖ Member of Korean Medical Association.
- ❖ Member of Korean Association of Internal Medicine.
- ❖ Member of Korean Cancer Study Group.
- ❖ Member of American Association of Cancer Research
- ❖ Member of Society for Immunotherapy of Cancer

### **Research Funding**

Title of Project: RASSF1A and Caveolin-1; A study for the identification of potential biomarkers for taxane sensitivity in Korean breast cancer patients.

- P.I.: Kyong Hwa Park, M.D. PhD
- Agency: Ministry of Health & Welfare
- Period: 2008. 9 - 2009. 8
- Annual Costs: KRW 30,000,000

Title of Project: Study of the role of IGF/HER-2 pathway in the carcinogenesis of breast cancer stem cells and development of IGF/HER-2 targeting peptide vaccine and CD4+T cell therapy.

- P.I.: Kyong Hwa Park, M.D. PhD
- Agency: National research foundation of Korea
- Period: 2009. 5 - 2012. 4
- Annual Costs: KRW 40,000,000

Title of Project: Study of the efficacy and safety of chemotherapeutics used in off-label in Korea

- P.I.: Kyong Hwa Park, M.D. PhD
- Agency: KFDA
- Period: 2012. 5 - 2012. 11

- Annual Costs: KRW 80,000,000

Title of Project: Development of immunotherapeutics targeting c-MET/HIF1 $\alpha$  to inhibit bone metastasis and elucidation of mechanism of action on bone microenvironment in breast cancer

- P.I.: Kyong Hwa Park, M.D. PhD  
- Agency: National research foundation of Korea  
- Period: 2016. 9 - 2019. 8  
- Annual Costs: KRW 50,000,000

Title of Project: Development of immunotherapeutics targeting c-MET/HIF1 $\alpha$  to inhibit bone metastasis and elucidation of mechanism of action on bone microenvironment in breast cancer

- P.I.: Kyong Hwa Park, M.D. PhD  
- Agency: National research foundation of Korea  
- Period: 2016. 9 - 2019. 8  
- Annual Costs: KRW 50,000,000

Title of Project: nano-Biofluignostic Research Center

- P.I.: Se-hyun Shin PhD  
- Agency: Ministry of Science, ICT and Future Planning  
- Period: 2016. 6 - 2022. 12  
- Annual Costs: KRW 100,000,000/1,200,000,000

## **Publications**

Park KH et al. Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.

Kim HS, Park KH. Et al. Oncology. 2016;91(5):274-282. Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea.

Park KH, Choi YJ, Kim KW, Ro KH, Kang CH, Song SH, Park JH. Jpn J Clin Oncol. 2016 Sep;46(9):845-9. doi: 10.1093/jjco/hyw081. Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive fibromatosis.

Seow WJ, Park KH et al. Hum Mol Genet. 2016 Dec 26. pii: ddw414. doi: 10.1093/hmg/ddw414. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations.

Kang J, Park JH, Lee HJ, Jo U, Park JK, Seo JH, Kim YH, Kim I, Park KH. Cancer Res Treat. 2016 Apr;48(2):715-26. doi: 10.4143/crt.2015.227. Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms.

Machiela MJ, Park KH et al. Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. *Int J Cancer*. 2015 Jul 15;137(2):311-9. doi: 10.1002/ijc.29393

Kang EJ, Choi YJ, Kim JS, Park KH, Oh SC, Seo JH, Kim HJ, Kang KW, Yu ES, Shin SW, Kim YH, Kim JS. Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer. *Chemotherapy*. 2014;60(2):91-8.

Kim HS, Lee SW, Choi YJ, Shin SW, Kim YH, Cho MS, Lee SN, Park KH. Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma. *Cancer Res Treat*. 2014 Oct 17. doi: 10.4143

Lee SY, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Kim ST. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin. *Am J Ther*. 2015 Jan 29

Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs J, Higgins D, Disis ML. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. *Cancer Res*. 2014 May 15;74(10):2710-8.

Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, O'Meara MM, Treuting PM, Lubet RA. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. *Cancer Prev Res (Phila)*. 2013 Dec;6(12):1273-82

Gil EY, Jo UH, Lee HJ, Kang J, Seo JH, Lee ES, Kim YH, Kim I, Phan-Lai V, Disis ML, Park KH. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. *Breast Cancer Res Treat*. 2014 Aug;147(1):69-80.

Lee JH, Kang SG, Kim ST, Kang SH, Choi IK, Park YJ, Oh SC, Sung DJ, Seo JH, Cheon J, Shin SW, Kim YH, Kim JS, Park KH. Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment. *Cancer Res Treat*. 2014 Apr;46(2):172-7.

Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. *Neoplasma*. 2014;61(3):352-62.

Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. *Tumour Biol*. 2014 Jan;35(1):277-86.

Cecil DL, Park KH, Gad E, Childs JS, Higgins DM, Plymate SR, Disis ML. T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity. *Breast Cancer Res Treat*. 2013 Jun;139(3):657-65.

Kim HS, Sung JS, Yang SJ, Kwon NJ, Jin L, Kim ST, Park KH, Shin SW, Kim HK, Kang JH, Kim JO, Park JY, Choi JE, Yoon H, Park CK, Yang KS, Seo JS, Kim YH. Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma. PLoS One. 2013 Dec 20;8(12):e81975

Park JH, Lee SW, Kim HS, Kang SG, Ko YH, Kim ST, Kang SH, Park YJ, Choi IK, Oh SC, Sung DJ, Seo JH, Cheon J, Kim YH, Kim JS, Park KH. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. Cancer Chemother Pharmacol. 2013 Apr;71(4):1033-9.

Kim ST, Park KH, Kim JS, Shin SW, Kim YH. Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. Cancer Res Treat. 2013 Mar;45(1):55-62.

Wnt5a is associated with cigarette smoke-related lung carcinogenesis via protein kinase C. Whang YM, Jo U, Sung JS, Ju HJ, Kim HK, Park KH, Lee JW, Koh IS, Kim YH. PLoS One. 2013;8(1):e53012

Lan Q, Park KH et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet 2012 Dec;44(12):1330-5.

Gil EY, Jo UH, Jeong H, Whang YM, Woo OH, Cho KR, Seo JH, Kim A, Lee ES, Koh I, Kim YH, Park KH. Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. 2012 April, Int J Oncol

Park Y, Shin SW, Kim YH, Park KH. RASSF1A and ERCC1 Expressions Might Be Predictive of Prognosis in Advanced, Recurrent, and Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with Docetaxel and Cisplatin. Onkologie 2012;35(11):673-82

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH. Tumor-infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients With Early Breast Cancer. Am J Clin Oncol. 2012 Apr 6

Park KH, Kim JS, Park Y, Seo HY, Park YJ, Choi IK, Oh SC, Seo JH, Kim CY, Jung KY, Shin SW, Kim YH, Kim JS, Lee NJ. Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea. Cancer Chemother Pharmacol. 2010 Sep;66(4):643-51

Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, Fintak P, Childs J, Dela Rosa C, Disis ML. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res. 2008 Oct 15;68(20):8400-9

Park KH, Han SGL, Whang YM, Lee HJ, Yoo YD, Lee JW, Shin SW, Kim YH. Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean population. Cancer Genet Cytogenet. 2006 Aug;169(1):39-44.

Park KH, Rho YH, Choi SJ, Hong SJ, Lee JH, Choi IK, Kim SJ, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Song GG, Kim JS. Acute arthritis of carpal bones secondary to metastatic gastric cancer. *Clin Rheumatol*. 2006 Mar;25(2):258-61

Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. *Cancer*. 2005 Jun 1;103(11):2338-43

Kyong Hwa Park, M.D., Byung Soo Kim, M.D., Sook Young Bae, M.D., Soo Young Yoon, M.D., Hye Ryoung Sul, M.D., Jong Gwon Choi, M.D., Hwa Jung Sung, M.D., So Young Yoon, M.D., In Keun Choi, M.D., Sang Cheul Oh, M.D., Jae Hong Seo, M.D., Chul Won Choi, M.D., Sang Won Shin, M.D., Yeul Hong Kim, M.D., and Jun Seok Kim, M.D. Activities of long term stored platelets. *The Korean Journal of Hematology*

Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Jong Eun Yeon, Byung Soo kim, Sang Won Shin, Yeul Hong kim, Kwan Soo Byun, Jun Suk Kim and Chang Hong Lee. Pirarubicin, UFT, leucovorin chemotherapy in non-embolizable and transcatheter arterial chemoembolization failed hepatocellular carcinoma patients; a phase II clinical study. *Cancer Research and Treatment* 2002;34:280-283.

Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients? *Asia Pac J Clin Oncol*. 2012 Jun;8(2):194-200

Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Kim YH, Shin SW. Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung Cancer. *Cancer Res Treat*. 2012 Mar;44(1):37-42

Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Varicella zoster virus infection during chemotherapy in solid cancer patients. *Oncology*. 2012;82(2):126-30

Kim HS, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee ES, Lee JB, Kim YH, Kim JS, Seo JH. The relationship between twin births and maternal risk of breast cancer: a meta-analysis. *Breast Cancer Res Treat*. 2012 Jan;131(2):671-7

Park Y, Choi YJ, Park SJ, Lee SR, Sung HJ, Park KH, Kim SJ, Choi CW, Jung KY, Kim BS. Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma. *Acta Haematol*. 2011;126(2):79-86.

Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy. *Oncology*. 2010;79(5-6):363-

Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. *Chemotherapy*. 2011;57(2):108-14

Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. *Clin Oncol (R Coll Radiol)*. 2012 Mar;24(2):105-11

Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. *Asia Pac J Clin Oncol*. 2011 Mar;7(1):82-7

Choi YJ, Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients. *Med Oncol*. 2012 Jun;29(2):582-8

Kang EJ, Choi YJ, Kim JS, Kim ST, Park KH, Choi IK, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. *Asia Pac J Clin Oncol*. 2010 Dec;6(4):286-91.

Hsiung CA, Lan Q, Hong YC, Chen CJ, Hosgood HD, Chang IS, Chatterjee N, Brennan P, Wu C, Zheng W, Chang GC, Wu T, Park JY, Hsiao CF, Kim YH, Shen H, Seow A, Yeager M, Tsai YH, Kim YT, Chow WH, Guo H, Wang WC, Sung SW, Hu Z, Chen KY, Kim JH, Chen Y, Huang L, Lee KM, Lo YL, Gao YT, Kim JH, Liu L, Huang MS, Jung TH, Jin G, Caporaso N, Yu D, Kim CH, Su WC, Shu XO, Xu P, Kim IS, Chen YM, Ma H, Shen M, Cha SI, Tan W, Chang CH, Sung JS, Zhang M, Yang TY, Park KH, Yuenger J, Wang CL, Ryu JS, Xiang Y, Deng Q, Hutchinson A, Kim JS, Cai Q, Landi MT, Yu CJ, Park JY, Tucker M, Hung JY, Lin CC, Perng RP, Boffetta P, Chen CY, Chen KC, Yang SY, Hu CY, Chang CK, Fraumeni JF Jr, Chanock S, Yang PC, Rothman N, Lin D. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. *PLoS Genet*. 2010 Aug 5;6(8).

Yang DS, Park KH, Woo OH, Woo SU, Kim AR, Lee ES, Lee JB, Kim YH, Kim JS, Seo JH. Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis. *Breast Cancer Res Treat*. 2011 Feb;125(3):849-53

Seo HY, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, Kim YH, Kim JS. Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. *Jpn J Clin Oncol*. 2010 Dec;40(12):1147-53

Woo SU, Park KH, Woo OH, Yang DS, Kim AR, Lee ES, Lee JB, Kim YH, Kim JS, Seo JH. Association of a TGF- $\beta$ 1 gene -509 C/T polymorphism with breast cancer risk: a meta-analysis. *Breast Cancer Res Treat*. 2010 Nov;124(2):481-5

Sung JS, Park KH, Kim YH. Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients. *Cancer Genet Cytogenet*. 2010 Apr 1;198(1):27-34.

Yang DS, Sung HJ, Woo OH, Park KH, Woo SU, Kim AR, Lee ES, Lee JB, Kim YH, Kim JS, Seo JH. Association of a progesterone receptor gene +331 G/A polymorphism with breast cancer risk: a meta-analysis. *Cancer Genet Cytogenet*. 2010 Jan 15;196(2):194-7.

Seo HY, Lee HJ, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Lee ES, Kim YH, Kim JS, Seo JH. Phase II study of vinorelbine monotherapy in anthracycline and

taxane pre-treated metastatic breast cancer. Invest New Drugs. 2011 Apr;29(2):360-5

Park Y, Kim DS, Park SJ, Seo HY, Lee SR, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. Leuk Res. 2010 Mar;34(3):294-300

Lee JB, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee ES, Kim YH, Kim JS, Seo JH. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs. 2011 Feb;29(1):182-8

Choi HS, Lee Y, Park KH, Sung JS, Lee JE, Shin ES, Ryu JS, Kim YH. Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population. J Hum Genet. 2009 May;54(5):298-303

Whang YM, Park KH, Jung HY, Jo UH, Kim YH. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines. Cancer. 2009 Mar 15;115(6):1253-66.

Jo UH, Han SG, Seo JH, Park KH, Lee JW, Lee HJ, Ryu JS, Kim YH. The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population. BMC Cancer. 2008 Dec 4;8:359

Seo JH, Sung HJ, Park KH, Choi IK, Oh SC, Shin SW, Kim YH, Kim JS, Kim AR, Lee JB, Koo BH. Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy. Invest New Drugs. 2009 Feb;27(1):67-73

Han SG, Park KH, Sung JS, Whang YM, Kim YJ, Shin ES, Lee JW, Lee HJ, Ryu JS, Choi IK, Seo JH, Kim YH. Single nucleotide polymorphisms of IGFBP-3 gene and lung cancer risk in a Korean population. Lung Cancer. 2008 Nov;62(2):152-61

Seo HY, Kim DS, Choi YS, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2009 Feb;63(3):433-9

Sung JS, Han SG, Whang YM, Shin ES, Lee JW, Lee HJ, Ryu JS, Choi IK, Park KH, Kim JS, Shin SW, Chu EK, Kim YH. Putative association of the single nucleotide polymorphisms in RASSF1A promoter with Korean lung cancer. Lung Cancer. 2008 Sep;61(3):301-8

Park SJ, Choi IK, Seo HY, Sung HJ, Park KH, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol. 2007;118(4):219-21

Choi IK, Seo HY, Sung HJ, Park KH, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer. Med Oncol. 2007;24(1):33-7.



Yoon SY, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity. *Acta Haematol.* 2007;118(1):30-7

Sung HJ, Kim SJ, Seo HY, Sul HR, Choi JG, Choi IK, Park KH, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. *Br J Haematol.* 2006 Jul;134(1):45-53.

Kim SJ, Seo HY, Choi JG, Sul HR, Sung HJ, Park KH, Choi IK, Oh SC, Yoon SY, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma *Cancer Chemother Pharmacol.* 2006 Apr;57(4):436-42

Yoon SY, Lee YJ, Seo JH, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. *Cell Res.* 2006 Jan;16(1):75-81.

Choi CW, Park KH, Choi IK, Kim SJ, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS Prevalence of iron deficiency anemia in community-dwelling older persons as measured by the transferrin receptor-ferritin index. *Acta Haematol.* 2005;114(3):180-2.

Choi CW, Lee J, Park KH, Choi IK, Kim SJ, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS Incidence of anemia in older Koreans: community-based cohort study. *Arch Gerontol Geriatr.* 2005 Nov-Dec;41(3):303-9

Choi CW, Cho WR, Park KH, Choi IK, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS, Lee J The cutoff value of serum ferritin for the diagnosis of iron deficiency in community-residing older persons. *Ann Hematol.* 2005 Jun;84(6):358-61

Oh SC, Park KH, Choi IK, Yoon SY, Kim SJ, Seo JH, Choi CW, Kim BS, Shin SW, Kim JS, Kim YH Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer. *Br J Cancer.* 2005 Mar 14;92(5):827-31

So Young Yoon M.D., Kyong Hwa Park, M.D., Sang Chul Oh, M.D., Jae Hong Seo, M.D., Chul Won Choi, M.D., Byung Soo Kim, M.D., Sang Won Shin, M.D., Yeul Hong Kim, M.D. and Jun Suk Kim, M.D. Phase II trial of Gemcitabine, UFT-E, Leucovorin Combination Chemotherapy in Advanced Pancreatic Adenocarcinoma. *Cancer Research and Treatment.* 2002;34:111-116

Seok Jin Kim, Hwa Jung Sung, Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, byung Soo kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim. Oral etoposide, ifosfamide and cisplatin in the treatment of extensive disease small cell lung cancer. *Cancer Research and Treatment.* 2002;34:421-425

Chul Won Choi, Kyong Hwa Park, So Young Yoon, Chang Won Paik, Jae Hong Seo, Kyung Mook Choi, Byung Soo Kim, Sei Hyun Baik, Sang Won Shin, Yeul Hong Kim,

Jun Suk Kim.The prevalence of anemia in elderly person over 60 yesrs. Korean J Med  
2001;60:249-253.

Signature : \_\_\_\_\_

Date : \_\_\_\_\_